QUEBEC CITY,
Jan. 13, 2014 /PRNewswire/ -
DiagnoCure Inc. (TSX: CUR; OTCQX: DGCRF) announced today that the
Corporation will release its fourth quarter and fiscal year 2013
operating results on January 16,
2014, at 4:00 p.m. (ET).
DiagnoCure's management will host a conference call the same day,
at 4:30 p.m. (ET). Interested
participants may listen to the call by dialing 1-888-390-0546 or
514-225-6995 and referencing code 50137031 approximately 15 minutes
prior to the call. The Corporation will also provide a live webcast
of the call. Interested participants may access the webcast on
DiagnoCure's website at www.diagnocure.com, through a link on the
Investors page - Presentations. A replay of the webcast will
be available on DiagnoCure's website for those unable to
participate in the live webcast.
About DiagnoCure
DiagnoCure (TSX: CUR; OTCQX: DGCRF) is a life
sciences corporation that develops and commercializes high-value
cancer diagnostic tests that increase clinician and patient
confidence in making critical treatment decisions. In 2008, the
Corporation launched a colorectal cancer staging test through its
U.S. CLIA laboratory. PrevistageTM GCC is currently available for
licensing. The Corporation has granted a worldwide exclusive
license on PCA3 to Gen-Probe, now a wholly-owned subsidiary of
Hologic Inc. operating as Hologic Gen-Probe, for the development
and commercialization of a prostate cancer test, DiagnoCure's
proprietary molecular biomarker. Hologic Gen-Probe's PROGENSA® PCA3
test is commercialized in Europe
under CE mark and is approved for commercialization in Canada and the
United States. For more information, please visit
www.diagnocure.com.
Forward‐looking statements
This release contains forward‐looking statements
that involve known and unknown risks, uncertainties and assumptions
that may cause actual results to differ materially from those
expected. By their very nature, forward‐looking statements are
based on expectations and hypotheses and also involve risks and
uncertainties, known and unknown, many of which are beyond
DiagnoCure's control. As a result, investors are cautioned not to
place undue reliance on these forward‐looking statements. The
forward-looking statements regarding the outcome of research and
development projects, clinical studies and future revenues are
based on management expectations. In addition, the reader is
referred to the applicable general risks and uncertainties
described in DiagnoCure's most recent Annual Information Form under
the heading "Risk Factors". DiagnoCure undertakes no obligation to
publicly update or revise any forward‐looking statements contained
herein unless required by the applicable securities laws and
regulations.
SOURCE DiagnoCure inc.
